Movement Alert｜PHARMARON Rises 3.06% in Regular Trading, CXO Sector Continues to Strengthen Ahead of Interim Results Review

Market Focus08-11

On August 11, PHARMARON rose 3.06% in regular trading, trading at 28.22 HKD/share, with turnover of 64.65 million HKD. The rally was driven by continued strength across the CXO sector and the approaching board meeting scheduled for August 20 to review H1 interim results.

The company previously guided H1 revenue of 7.47 billion to 7.67 billion yuan, representing 16%-19% year-over-year growth, with net profit growth of 4%-10%. Notably, newly signed orders surged over 30% in H1, with small-molecule CDMO new orders growing over 50%, reflecting robust demand recovery. Industry leader WuXi AppTec reported H1 revenue growth of 38.93% and net profit growth of 29.43%, reinforcing sector-wide momentum and valuation recovery.

Within the Life Sciences Tools and Services sector, peers also advanced: WuXi AppTec rose 1.62%, WuXi Biologics gained 2.52%, GenScript Biotech climbed 2.90%, and XtalPi added 4.24%. JPMorgan increased its stake by approximately 1.29 million shares in July at 22.11 HKD per share, bringing its holding to 7.32%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1179316059?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-11 09:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179316059","market":"hk","top_or_hot":-1,"title":"Movement Alert｜PHARMARON Rises 3.06% in Regular Trading, CXO Sector Continues to Strengthen Ahead of Interim Results Review","media":"Market Focus","content":"<p><p>On August 11, PHARMARON rose 3.06% in regular trading, trading at 28.22 HKD/share, with turnover of 64.65 million HKD. The rally was driven by continued strength across the CXO sector and the approaching board meeting scheduled for August 20 to review H1 interim results.</p><p>The company previously guided H1 revenue of 7.47 billion to 7.67 billion yuan, representing 16%-19% year-over-year growth, with net profit growth of 4%-10%. Notably, newly signed orders surged over 30% in H1, with small-molecule CDMO new orders growing over 50%, reflecting robust demand recovery. Industry leader WuXi AppTec reported H1 revenue growth of 38.93% and net profit growth of 29.43%, reinforcing sector-wide momentum and valuation recovery.</p><p>Within the Life Sciences Tools and Services sector, peers also advanced: WuXi AppTec rose 1.62%, WuXi Biologics gained 2.52%, GenScript Biotech climbed 2.90%, and XtalPi added 4.24%. JPMorgan increased its stake by approximately 1.29 million shares in July at 22.11 HKD per share, bringing its holding to 7.32%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜PHARMARON Rises 3.06% in Regular Trading, CXO Sector Continues to Strengthen Ahead of Interim Results Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜PHARMARON Rises 3.06% in Regular Trading, CXO Sector Continues to Strengthen Ahead of Interim Results Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-11 09:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 11, PHARMARON rose 3.06% in regular trading, trading at 28.22 HKD/share, with turnover of 64.65 million HKD. The rally was driven by continued strength across the CXO sector and the approaching board meeting scheduled for August 20 to review H1 interim results.</p><p>The company previously guided H1 revenue of 7.47 billion to 7.67 billion yuan, representing 16%-19% year-over-year growth, with net profit growth of 4%-10%. Notably, newly signed orders surged over 30% in H1, with small-molecule CDMO new orders growing over 50%, reflecting robust demand recovery. Industry leader WuXi AppTec reported H1 revenue growth of 38.93% and net profit growth of 29.43%, reinforcing sector-wide momentum and valuation recovery.</p><p>Within the Life Sciences Tools and Services sector, peers also advanced: WuXi AppTec rose 1.62%, WuXi Biologics gained 2.52%, GenScript Biotech climbed 2.90%, and XtalPi added 4.24%. JPMorgan increased its stake by approximately 1.29 million shares in July at 22.11 HKD per share, bringing its holding to 7.32%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03759","symbol_name":"康龙化成","start_time":0,"source_url":"","article_id":"1179316059","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179316059","pubTimestamp":1786413109,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 11, PHARMARON rose 3.06% in regular trading, trading at 28.22 HKD/share, with turnover of 64.65 million HKD. The rally was driven by continued strength across the CXO sector and the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03759":"康龙化成"},"translate_title":"走势提醒|康龙化成常规交易上涨3.06%，CXO板块在中期业绩审查前继续走强","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03759":1},"content_text":"On August 11, PHARMARON rose 3.06% in regular trading, trading at 28.22 HKD/share, with turnover of 64.65 million HKD. The rally was driven by continued strength across the CXO sector and the approaching board meeting scheduled for August 20 to review H1 interim results.The company previously guided H1 revenue of 7.47 billion to 7.67 billion yuan, representing 16%-19% year-over-year growth, with net profit growth of 4%-10%. Notably, newly signed orders surged over 30% in H1, with small-molecule CDMO new orders growing over 50%, reflecting robust demand recovery. Industry leader WuXi AppTec reported H1 revenue growth of 38.93% and net profit growth of 29.43%, reinforcing sector-wide momentum and valuation recovery.Within the Life Sciences Tools and Services sector, peers also advanced: WuXi AppTec rose 1.62%, WuXi Biologics gained 2.52%, GenScript Biotech climbed 2.90%, and XtalPi added 4.24%. JPMorgan increased its stake by approximately 1.29 million shares in July at 22.11 HKD per share, bringing its holding to 7.32%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1179316059","isCrawlerRequest":true}